A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

RSPCA WORMaway 50/144/150 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:
Active substances:

Praziquantel	50 mg
Pyrantel embonate	144 mg
Febantel	150 mg

3. PACKAGE SIZE

2 tablets
4 tablets

4. TARGET SPECIES

Dogs

5. INDICATIONS

FOR THE TREATMENT OF ROUNDWORMS, HOOKWORMS AND TAPEWORMS IN DOGS

For the treatment of mixed infestations with roundworms, hookworms and tapeworms in adult dogs and puppies:

Nematodes
Ascarids: *Toxocara canis*, *Toxascaris leonina* (late immature forms and mature forms)
Hookworms: *Uncinaria stenocephala*, *Ancylostoma caninum* (adults)
Cestodes
Tapeworms: *Taenia* spp., *Dipylidium caninum*

6. ROUTES OF ADMINISTRATION

Read the package leaflet before use.
Oral use.
Dosage: 1 tablet per 10 kg body weight (15 mg febantel, 14.4 mg pyrantel and 5 mg praziquantel per kg of bodyweight), according to the table below:

Weight of dog	Tablets
2 kg - 2.5 kg	¼ tablet
2.5 kg - 5 kg	½ tablet
5 kg - 7.5 kg	¾ tablet
7.5 kg - 10 kg	1 tablet
10 kg - 15 kg	1 ½ tablets
15 kg - 20 kg	2 tablets
20 kg - 25 kg	2 ½ tablets
25 kg - 30 kg	3 tablets
30 kg - 35 kg	3 ½ tablets
35 kg - 40 kg	4 tablets

7. WITHDRAWAL PERIOD

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.
User Warnings
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician. Wash hands after use.
Keep the product in the outer package until ready to use.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto

14. MARKETING AUTHORISATION NUMBER

Vm 01656/5006
Vm 01656/3006

15. BATCH NUMBER

Lot {numbe

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

Blister

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

RSPCA WORMaway

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

50/144/150 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

KRKA

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

RSPCA WORMaway 50/144/150 mg tablets for dogs

2. Composition

Each tablet contains:
Active substances:

Praziquantel	50 mg
Pyrantel embonate	144 mg
Febantel	150 mg

Yellow coloured, round, biconvex tablets with visible darker spots, cross-scored on one side.
The tablets can be divided into halves or quarters.

3. Target species

Dogs (small and medium size)

4. Indications for use

For the treatment of mixed infestations with the following roundworms and tapeworms in adult dogs and puppies:
Nematodes
Ascarids: *Toxocara canis*, *Toxascaris leonina* (late immature forms and mature forms)
Hookworms: *Uncinaria stenocephala*, *Ancylostoma caninum* (adults)
Cestodes
Tapeworms: *Taenia* spp., *Dipylidium caninum*

Roundworms and tapeworms are parasites that live in the gut. If left untreated they can cause your dog to become unwell. Treating these infestations will reduce the risk of other animals and humans being exposed to worm infections.

5. Contraindications

Do not use simultaneously with piperazine compounds as piperazine may block the action of pyrantel embonate contained in the veterinary medicinal product. Other worming veterinary medicinal products may contain piperazine.
Do not exceed the stated dosage when treating pregnant bitches.
Do not use in bitches during the first two-thirds of pregnancy.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs younger than 2 weeks of age and/or weighing less than 2 kg.
Do not use simultaneously with other deworming veterinary medicinal products without veterinary advice.

6. Special warnings

Special warnings for each target species:
Fleas serve as intermediate hosts for one common type of tapeworm – *Dipylidium caninum*. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.
Dogs may become infected with worms by eating insects (including fleas and lice), birds, small rodents, rabbits or raw offal from affected sheep, goats and cattle. Dogs will continue to be re-infected unless the route of infection is controlled e.g. treating a flea infestation or preventing a dog from scavenging or hunting.
Parasite resistance to any particular class of anthelmintic may develop following frequent use, repeated use, or underdosing of an anthelmintic of that class.

Special precautions for use in animals:
Any part-used tablets should be discarded.
Not for use in dogs younger than 2 weeks and/or weighing less than 2 kg.
Do not exceed the stated dose, especially when treating pregnant bitches.
In dogs less than 6 weeks old, tapeworm infections are highly uncommon. Treatment of animals less than 6 weeks old with a fixed combination veterinary medicinal product against cestodes and nematodes may, therefore, not be necessary.
To minimise the risk of reinfestation and new infestation, excreta should be collected and properly disposed of for 24 hours following treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In the interests of good hygiene, persons administering the tablet directly to a dog or by adding it to the dog's food, should wash their hands afterwards.
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.

Pregnancy:
Do not use in bitches during the first two-thirds of pregnancy.
Consult a veterinary surgeon before treating pregnant animals for roundworms.

Lactation:
The veterinary medicinal product may be used during lactation (see Section “Advice on correct administration”).

Interaction with other medicinal products and other forms of interaction:
Do not use simultaneously with piperazine as the anthelmintic effects of pyrantel and piperazine (used in many worming veterinary medicinal products for dogs) may be antagonised.
Do not use simultaneously with any other deworming veterinary medicinal products.
If your dog receives other veterinary medicinal products, check with a veterinary surgeon or pharmacist before using this veterinary medicinal product.

Concurrent use with other cholinergic compounds can lead to toxicity.
Simultaneous administration of compounds that inhibit the activity of acetylcholinesterase - AChE (e.g.organophosphates) may increase systemic effects of pyrantel.
Plasma concentrations of praziquantel may be decreased by concomitant administration with drugs that increase the activity of cytochrome P-450 enzymes (e.g. dexamethasone, phenobarbital).

Overdose (symptoms, emergency procedures, antidotes), if necessary:
Benzimidazoles possess wide safety margin. Pyrantel is not absorbed systematically to any extent. Praziquantel also has a wide safety margin, and is well tolerated at up to five times the recommended dose.

7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Loose stool*, Diarrhoea*, Vomiting*

*Transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

For oral administration.
It is important to follow the treatment recommendations as presented here. Do not deviate from the recommendations without the advice of your veterinary surgeon.

The recommended dose rates are: 15 mg/kg body weight febantel, 14.4 mg/kg pyrantel and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 10 kg body weight, according to the table below.
Tablets may be halved/quartered to allow accuracy of dosing.

Weight of dog	Tablets
Over 2 kg up to 2.5 kg	¼ tablet
Over 2.5 kg up to 5 kg	½ tablet
Over 5 kg up to 7.5 kg	¾ tablet
Over 7.5 kg up to 10 kg	1 tablet
Over 10 kg up to 15 kg	1 ½ tablets
Over 15 kg up to 20 kg	2 tablets
Over 20 kg up to 25 kg	2 ½ tablets
Over 25 kg up to 30 kg	3 tablets
Over 30 kg up to 35 kg	3 ½ tablets
Over 35 kg up to 40 kg	4 tablets

The tablet(s) can be given directly to the dog or disguised in food. No restriction of access to food is required either before or after administration of the veterinary medicinal product.

Dogs weighing less than 2 kg should not be treated with the veterinary medicinal product, because correct dosing of such dogs may not be feasible.

Puppies may be wormed with this veterinary medicinal product from 2 weeks of age and every 2 weeks until 12 weeks of age. Thereafter they should be treated at 3 monthly intervals until 6 months of age. It is advisable to treat the bitch at the same time as the puppies.
For the control of *Toxocara*, nursing bitches should be dosed 2 weeks after giving birth and every 2 weeks until weaning.
For adult dogs, a single dose should be used. The advice of a veterinarian should be sought regarding the need for and frequency of repeat treatment.

If signs of disease persist or appear, consult a veterinary surgeon.

9. Advice on correct administration

To ensure administration of a correct dose, body weight should be determined as accurately as possible.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.
This medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product not subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 01656/5006
Vm 01656/3006

OPA/Al/PVC-Al blister: 2 tablets (1 blister with 2 tablets), in a box.
OPA/Al/PVC-Al blister: 4 tablets (2 blisters with 2 tablets), in a box.
Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Manufacturer responsible for batch release:
KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Local representatives and contact details to report suspected adverse reactions:
KRKA UK Ltd
United Kingdom
Tel: 02071 646 156
info.uk@krka.biz

17. Other information

AVM-GSL

For animal treatment only.

Approved 15 June 2026
Gavin Hall